In vitro and in vivo interactions of recent cephalosporins with gentamicin and amikacin.
The in vivo interactions of the aminoglycosides gentamicin and amikacin with the newer cephalosporins cefotaxime, ceftriaxone, ceftazidime and moxalactam were studied in 48 volunteers (28 males, 20 females, median age 54) who consented to participate in the trial. Patients were divided in eight groups according to all possible aminoglycoside/cephalosporin combinations. The in vivo trial was developed in two phases: aminoglycoside alone vs. aminoglycoside/cephalosporin. Each patient served as his own control. The differences in the aminoglycoside blood levels between the two phases were not statistically significant, except at the first post-dose hour in the gentamicin-ceftriaxone combination and at the first and sixth post-dose hours in the amikacin-moxalactam combinations. The in vitro interactions of the same combinations were partly correlated with the in vivo findings.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000378:metabolism*; D002511:Cephalosporins / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D005839:Gentamicins / Q000378:metabolism*; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged
D002511:Cephalosporins; D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin